Sign in
TALS Stock Price, Chart, Stats & News
Talaris Therapeutics, Inc.
Save
Talaris Therapeutics, Inc. (TALS) does not currently pay a dividend.
116.44M
Market cap
–
Current P/E
–
Forward P/E
TALS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 3.20% |
ROA | -35.35% |
ROE | -32.82% |
D/E | 0.00x |
Interest coverage ratio | -31.75x |
TALS valuation
P/E | – |
P/S | – |
P/B | 0.27x |
P/CF | -0.67x |
P/FCF | -1.12x |
P/OCF | -0.67x |
PEG | 0.16x |
EV multiple | -1.19x |
About
Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation.
Similar securities
Based on sector and market capitalization
Report issue